Correction: Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein (Oncogene, (2013), 32, 17, (2179-2188), 10.1038/onc.2012.236);Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein

Oncogene

Volumn 32, Issue 17, 2013, Pages 2179-2188

  Jin, C ^a   Rajabi, H ^a   Rodrigo, C M ^b   Porco, J A ^b   Kufe, D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Boston University   (United States)

Author keywords

AKT; mTOR; MUC1 C; PDCD4; silvestrol; translation

Indexed keywords

INITIATION FACTOR 4A; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUC1 CARBOXY TERMINAL ONCOPROTEIN; NEU DIFFERENTIATION FACTOR; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; RIBOSOMAL PROTEIN S6 KINASE 1; RNA HELICASE; S6 KINASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSLATION; SIGNAL TRANSDUCTION; UPREGULATION;

MAMMALIA;

EID: 84870037639     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-021-01727-3     Document Type: Erratum

References (44)

1. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009; 136: 731-745.
2. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23: 3189-3199. (Pubitemid 38638830)
3. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007; 21: 3232-3237. (Pubitemid 350277750)
4. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 307-318.
5. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1-And betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006; 314: 467-471. (Pubitemid 44628968)
6. Rogers Jr GW, Komar AA, Merrick WC. eIF4A: the godfather of the DEAD box helicases. Prog Nucleic Acid Res Mol Biol 2002; 72: 307-331.
7. Blagden SP, Willis AE. The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol 2011; 8: 280-291.
8. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008; 118: 2651-2660. (Pubitemid 351949792)
9. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009; 113: 4656-4666.
10. Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J et al. Targeting capdependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med 2011; 208: 1799-1807.
11. Kufe D. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874-885.
12. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 2007; 27: 992-1004. (Pubitemid 47488189)
13. Schroeder J, Thompson M, Gardner M, Gendler S. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-Activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001; 276: 13057-13064.
14. Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, Thompson MC et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004; 23: 5739-5747. (Pubitemid 39093019)
15. Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007; 26: 1693-1701. (Pubitemid 46426203)
16. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Therap 2011; 10: 806-816.
17. Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-Apoptotic PI3K/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 2004; 279: 20607-20612. (Pubitemid 38656454)
18. Li Y, Liu D, Chen D, Kharbanda S, Kufe D. Human DF3/MUC1 carcinoma-Associated protein functions as an oncogene. Oncogene 2003; 22: 6107-6110. (Pubitemid 37175889)
19. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks GSK3b-mediated phosphorylation and degradation of b-catenin. Cancer Res 2005; 65: 10413-10422. (Pubitemid 41743735)
20. Yin L, Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 2003; 278: 35458-35464. (Pubitemid 37102316)
21. Ren J, Agata N, Chen D, Li Y, Yu W-H, Huang L et al. Human MUC1 carcinomaassociated protein confers resistance to genotoxic anti-cancer agents. Cancer Cell 2004; 5: 163-175. (Pubitemid 38283802)
22. Yin L, Kharbanda S, Kufe D. Mucin 1 oncoprotein blocks hypoxia-inducible factor 1 alpha activation in a survival response to hypoxia. J Biol Chem 2007; 282: 257-266. (Pubitemid 47076647)
23. Ahmad R, Raina D, Joshi MD, Kawano T, Kharbanda S, Kufe D. MUC1-C oncoprotein functions as a direct activator of the NF-kB p65 transcription factor. Cancer Res 2009; 69: 7013-7021.
24. Ahmad R, Rajabi H, Kosugi M, Joshi M, Alam M, Vasir B et al. MUC1-C oncoprotein promotes STAT3 activation in an auto-inductive regulatory loop. Sci Signal 2011; 4: ra9.
25. Raina D, Ahmad R, Joshi M, Yin L, Wu Z, Kawano T et al. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009; 69: 5133-5141.
26. Joshi MD, Ahmad R, Raina D, Rajabi H, Bubley G, Kharbanda S et al. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther 2009; 8: 3056-3065.
27. Zhou J, Rajabi H, Kufe D. MUC1-C oncoprotein is a target for small molecule inhibitors. Mol Pharm 2011; 79: 886-893.
28. Newton R, Cambridge L, Hart LA, Stevens DA, Lindsay MA, Barnes PJ. The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes. Br J Pharmacol 2000; 130: 1353-1361. (Pubitemid 30488600)
29. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010; 70: 2146-2157.
30. Kong D, Yamori T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem 2009; 16: 2839-2854.
31. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res 2005; 65: 11282-11286. (Pubitemid 41821683)
32. Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 2005; 65: 6034-6041. (Pubitemid 40994387)
33. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998; 12: 3663-3674. (Pubitemid 29019647)
34. Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 2001; 490: 142-152. (Pubitemid 32171933)
35. Li Q, Lau A, Morris TJ, Guo L, Fordyce CB, Stanley EF. A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by quantitative immunocolocalization. J Neurosci 2004; 24: 4070-4081. (Pubitemid 38544233)
36. Rodrigo C, Cencic R, Roche S, Pelletier J, Porco Jr J. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies. J Med Chem 2012; 55: 558-562.
37. Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J et al. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 2003; 422: 322-326. (Pubitemid 36378360)
38. Hsieh AC, Truitt ML, Ruggero D. Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer 2011; 105: 329-336.
39. Li Y, Ren J, Yu W, Li G, Kuwahara H, Yin L et al. The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and b-catenin. J Biol Chem 2001; 276: 35239-35242.
40. Wedeken L, Singh P, Klempnauer KH. Tumor suppressor protein Pdcd4 inhibits translation of p53 mRNA. J Biol Chem 2011; 286: 42855-42862.
41. Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC et al. mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol 2011; 12: 235-245.
42. Hwang BY, Su BN, Chai H, Mi Q, Kardono LB, Afriastini JJ et al. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J Org Chem 2004; 69: 3350-3358. (Pubitemid 38621283)
43. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 2009; 4: e5223.
44. Gerard B, Cencic R, Pelletier J, Porco Jr JA. Enantioselective synthesis of the complex rocaglate (-)-silvestrol. Angew Chem Int Ed Engl 2007; 46: 7831-7834. (Pubitemid 47612915)